VENTANA MEDICAL SYSTEMS, INC.;ROCHE SEQUENCING SOLUTIONS INC.;Charité - Universitätsmedizin Berlin Gliedkörperschaft der Freien Universität Berlin Und der Humbold
发明人:
Pia Herrmann,Katharina Ilm,Katherine F. Leith,Andrea Muranyi,Ulrich-Peter Rohr,Kandavel Shanmugam,Shalini Singh,Ulrike Stein
申请号：
US16412057
公开号：
US20190269716A1
申请日:
2019.05.14
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A combination of mismatch repair (MMR) and Metastasis Associated in Colon Cancer 1 (MACC1) gene expression status of the patient serve as a basis for risk stratification of early stage colon cancer patients. Patients with defective MMR (dMMR) status have improved survival and do not benefit from 5-fluorouracil (5-FU) therapies. In contrast, patients with a proficient MMR (pMMR) status have a higher risk of recurrence and worse survival. The pMMR patients are then further stratified on the basis of MACC1 gene expression. Patients with a pMMR status and a low MACC1 expression have a favorable prognosis similar to patients having a dMMR status, whereas patients having a pMMR status and high MACC1 expression have a less favorable prognosis.
